Skip to main content

Table 2 U-NGAL, SCr, FENa, urine albumin, and AKI in 146 very preterm neonates postnatal day 3

From: Urinary Neutrophil Gelatinase-associated Lipocalin in the evaluation of Patent Ductus Arteriosus and AKI in Very Preterm Neonates: a cohort study

 

no PDA

PDA

small PDA

large PDA

n = 79

n = 67

n = 26

n = 41

U-NGAL day 3 (μg/l)

104 (79; 136)

158 (125; 201)*

177 (117; 266)*

148 (110; 200)*

U-NGAL day 6 (μg/l)

87 (63; 118)

139 (103; 190)*

166 (103; 267)*

126 (83; 190)

SCr (μmol/l)

78 (75; 82)

78 (75; 82)

78 (73; 84)

78 (74; 83)

Urinary albumin (mg/l)

29 (24; 36)

62 (51; 77)*

56 (41; 76)*

67 (51; 90)*

FENa (%)

2.6 (2.3; 2.9)

3.6 (3.2; 4.2)*

3.8 (3.0; 4.8)*

3.6 (3.0; 4.2)*

AKI, number (%)

1 (1)

6 (9)*

2 (8)

4 (10)*

  1. NGAL urine neutrophil gelatinase-associated lipocalin, SCr serum creatinine, AKI acute kidney injury, FENa fractional excretion of sodium, PDA diameter <1.5 mm small PDA, PDA diameter ≥1.5 mm large PDA. Values are geometric mean (95% confidence interval) or number (percentage). *p < 0.05 compared to neonates with no PDA. U-NGAL day 6 was only measured in 126 neonates